Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma
The FASEB Journal · 2025
DOI: 10.1096/fj.202500857r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Feifeng Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou M…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Epigenesis, Genetic, Symporters. Die Arbeit nennt 38 Literaturangaben. Gefördert von: MOST|NSFC|NSFC-Zhejiang Joint Fund| |Natural Science Foundation of Zhejiang Province (ZJNSF), MOST|NSFC|NSFC-Zhejiang Joint Fund| |Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
The poor prognosis of clear cell renal cell carcinoma (ccRCC) is primarily attributed to inherent resistance and malignant progression, yet the underlying mechanism and effective strategies remain poorly understood. Renal drug transporters play an indispensable role in regulating the intracellular concentration of tumor cells. Therefore, this study aims to investigate the role of proton‐coupled oligopeptide transporter 2 (PEPT2) in ccRCC. PEPT2 was found to be downregulated in ccRCC tissues and cell lines, and its low expression was associated with an unfavorable prognosis in ccRCC patients. Overexpression of PEPT2 inhibited cell proliferation and metastasis both in vitro and in vivo. Furthermore, the transcriptional repression of PEPT2 was attributed to DNMT3A/B mediated methylation of its promoter, which could be reversed by the epigenetic inhibitor decitabine, leading to the restored expression and functional transport activity of PEPT2. Importantly, the combination treatment with decitabine (an epigenetic inhibitor) and a lenalidomide‐dipeptide conjugate (a substrate for PEPT2) significantly enhanced cytotoxicity against ccRCC cells both in vitro and in vivo. Our investigation into the epigenetic repression of PEPT2 promoters has revealed a significant role in the progression of ccRCC. Furthermore, our findings demonstrate that the combination of PEPT2‐targeted lenalidomide with epigenetic therapy effectively enhances cytotoxicity in ccRCC cells. This study provides compelling experimental evidence for the potential therapeutic benefit of targeting PEPT2 in the treatment of ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
- Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, China.
- Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, China.
- Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
ORCID-Profile: Tong Xu
Förderung
- MOST|NSFC|NSFC-Zhejiang Joint Fund| |Natural Science Foundation of Zhejiang Province (ZJNSF)
- MOST|NSFC|NSFC-Zhejiang Joint Fund| |Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
- Natural Science Foundation of Zhejiang Province
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
Zitieren
APA
Song, F., Zhang, Q., Zhang, Z., Xu, T., Qin, H., Lou, Y., Zhang, W., Liu, F., Zhang, Y., & Huang, P. (2025). Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma. The FASEB Journal. https://doi.org/10.1096/fj.202500857r
Vancouver
Song F, Zhang Q, Zhang Z, Xu T, Qin H, Lou Y, et al. Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma. The FASEB Journal. 2025. doi:10.1096/fj.202500857r
BibTeX
@article{Song2025,
author = {Song, Feifeng and Zhang, Qi and Zhang, Zhentao and Xu, Tong and Qin, Hui and Lou, Yutao and Zhang, Wanli and Liu, Feng and Zhang, Yiwen and Huang, Ping},
title = {Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500857r}
}
EUVIMED